GLP-1s Are Getting Cheaper: Now Is the Time to Act

Why It Matters

Lower GLP‑1 prices could curb rising employer health‑care costs while satisfying soaring employee demand, making drug‑coverage strategy a competitive advantage for benefits leaders.

Key Takeaways

• Novo Nordisk to cut GLP-1 prices by ~50% next year
• 60% of employers already cover GLP-1s for weight loss
• 93% of employees would use GLP-1s if employer‑covered
• Employers using eligibility criteria and cost‑sharing to manage spend
• GLP-1s represent >20% of employer pharma spend

Pulse Analysis

The GLP‑1 market is at a turning point. Novo Nordisk’s pledge to slash the list price of Ozempic, Wegovy and other GLP‑1 agents by roughly half—bringing the monthly cost to about $675—addresses long‑standing affordability concerns that have limited broader adoption. At the same time, employee interest in these drugs for both diabetes management and weight loss has surged, with usage among working‑age Americans doubling over the past three years. This price shift is expected to accelerate uptake and reshape employer benefit strategies.

Employer surveys reveal a rapid evolution in coverage design. About 60% of organizations now cover GLP‑1s for weight‑loss indications, and 46% apply specific eligibility criteria while 13% offer relatively unrestricted access. The CHRO Association’s research shows that 93% of workers whose plans lack coverage would enroll if the drugs were covered, underscoring the pressure on benefits teams. To balance demand with cost, many firms are drawing sharper lines between diabetes treatment and elective weight‑loss use, employing higher deductibles, co‑pays, and tiered pharmacy networks, and instituting clinical monitoring and maintenance programs.

The financial stakes are significant. GLP‑1s now represent more than 20% of employer pharmaceutical spend, contributing to a broader trend where specialty drugs drive health‑care cost inflation. With prescription drugs accounting for roughly one‑third of total employer health spend and projected to rise 9.5% this year, the price reduction offers a rare opportunity to mitigate budget impact. Employers are exploring alternative purchasing models, value‑based contracts, and tighter formulary management to capture savings. As coverage expands, the focus will shift from merely managing expense to optimizing health outcomes, positioning GLP‑1 benefits as a strategic lever for talent attraction and retention.